Patient-Reported Outcomes As Important Predictors of Apremilast Persistence: A Pooled Analysis of Real-World Data
Author(s)
Lisa Lebherz, MSc1, Christine Blome, PhD1, Matthias Augustin, MD1, Myriam Cordey, PhD2, Georgios Papageorgiou, PhD3, David Neasham, PhD3, Kathy T Tran, PhD2.
1Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, 2Amgen Inc., Thousand Oaks, CA, USA, 3Amgen UK Ltd, Cambridge, United Kingdom.
1Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, 2Amgen Inc., Thousand Oaks, CA, USA, 3Amgen UK Ltd, Cambridge, United Kingdom.
Presentation Documents
OBJECTIVES: Identify psoriasis patients who persisted on apremilast, focusing on patient-reported outcomes to improve persistence considering patients’ treatment preferences.
METHODS: Data were pooled from four observational, longitudinal, multicentre studies (REALIZE, OTELO, APPRECIATE, DARWIN) including 1,198 patients with moderate-to-severe plaque psoriasis initiating apremilast in clinical practice across 10 European countries. Backwards elimination logistic regression was performed to predict 6-month apremilast persistence (yes/no), with the following predictors: sex; age; baseline BMI; previous treatment; number of comorbidities; time to apremilast initiation from psoriasis diagnosis; special areas (yes/no); baseline Psoriasis Area and Severity Index (PASI); baseline Dermatology Life Quality Index (DLQI); adverse events (AEs, yes/no); and patient-reported 6-month treatment satisfaction (Treatment Satisfaction Questionnaire for Medication [TSQM-9]) and patient benefit index (PBI).
RESULTS: Of 1,198 patients, 865 (72.2%) persisted on apremilast at 6 months. Overall mean age at baseline was 52.5 years and 45.9% were female. Most had prior systemic therapy (55.8% non-biologic, 12.5% biologic) and special area involvement (81.2% overall): scalp (60.3%), nails (31.6%), palmoplantar (26.8%), face (23.1%), and genital (20.3%). Persistent patients were more often systemic naive (27.3%) than non-persistent patients (15.7%). 64.9% and 25.1% of persistent and non-persistent patients did not experience AEs, respectively. Mean [SD] TSQM-9 global satisfaction score was 58.9 [29.0], and higher in persistent (67.7 [23.4]) versus non-persistent patients (26.1 [23.8]). The correlation between TSQM-9 global satisfaction score and PBI was high (R=0.747); mean [SD] PBI score was higher in persistent (2.8 [1.1]) than non-persistent (1.3 [1.2]) patients. 6-month persistence was significantly associated with being systemic-naive (odds ratio [95%CI]: 1.97 [1.11, 3.60]), no AE reported (3.97 [2.59, 6.14]), and higher TSQM-9 global satisfaction score (1.06 [1.05, 1.07]) denoting higher satisfaction.
CONCLUSIONS: Patient-reported global treatment satisfaction was significantly associated with 6-month apremilast persistence. Understanding patient-perceived satisfaction and benefits throughout the treatment journey is integral to ensuring persistence on psoriatic treatments.
METHODS: Data were pooled from four observational, longitudinal, multicentre studies (REALIZE, OTELO, APPRECIATE, DARWIN) including 1,198 patients with moderate-to-severe plaque psoriasis initiating apremilast in clinical practice across 10 European countries. Backwards elimination logistic regression was performed to predict 6-month apremilast persistence (yes/no), with the following predictors: sex; age; baseline BMI; previous treatment; number of comorbidities; time to apremilast initiation from psoriasis diagnosis; special areas (yes/no); baseline Psoriasis Area and Severity Index (PASI); baseline Dermatology Life Quality Index (DLQI); adverse events (AEs, yes/no); and patient-reported 6-month treatment satisfaction (Treatment Satisfaction Questionnaire for Medication [TSQM-9]) and patient benefit index (PBI).
RESULTS: Of 1,198 patients, 865 (72.2%) persisted on apremilast at 6 months. Overall mean age at baseline was 52.5 years and 45.9% were female. Most had prior systemic therapy (55.8% non-biologic, 12.5% biologic) and special area involvement (81.2% overall): scalp (60.3%), nails (31.6%), palmoplantar (26.8%), face (23.1%), and genital (20.3%). Persistent patients were more often systemic naive (27.3%) than non-persistent patients (15.7%). 64.9% and 25.1% of persistent and non-persistent patients did not experience AEs, respectively. Mean [SD] TSQM-9 global satisfaction score was 58.9 [29.0], and higher in persistent (67.7 [23.4]) versus non-persistent patients (26.1 [23.8]). The correlation between TSQM-9 global satisfaction score and PBI was high (R=0.747); mean [SD] PBI score was higher in persistent (2.8 [1.1]) than non-persistent (1.3 [1.2]) patients. 6-month persistence was significantly associated with being systemic-naive (odds ratio [95%CI]: 1.97 [1.11, 3.60]), no AE reported (3.97 [2.59, 6.14]), and higher TSQM-9 global satisfaction score (1.06 [1.05, 1.07]) denoting higher satisfaction.
CONCLUSIONS: Patient-reported global treatment satisfaction was significantly associated with 6-month apremilast persistence. Understanding patient-perceived satisfaction and benefits throughout the treatment journey is integral to ensuring persistence on psoriatic treatments.
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
PCR181
Topic
Patient-Centered Research
Topic Subcategory
Adherence, Persistence, & Compliance, Patient-reported Outcomes & Quality of Life Outcomes
Disease
SDC: Systemic Disorders/Conditions (Anesthesia, Auto-Immune Disorders (n.e.c.), Hematological Disorders (non-oncologic), Pain)